FDA label
What is enoxaparin used for?
The FDA-approved uses of enoxaparin, quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for enoxaparin sodium (injection) lists 4 uses: Prophylaxis of Deep Vein Thrombosis; Treatment of Acute Deep Vein Thrombosis; Prophylaxis of Ischemic Complications of Unstable Angina and Non-Q-Wave Myocardial Infarction; Treatment of Acute ST-Segment Elevation Myocardial Infarction.
Run it in Rivvi
Which 2027 plans near you dropped or restricted enoxaparin?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Enoxaparin Sodium, injection
Indications and Usage, quoted from the label by BluePoint Laboratories (ANDA076684). Cross-references to other label sections are left out.
Prophylaxis of Deep Vein Thrombosis
Enoxaparin Sodium Injection is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):
- in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies ]
- in patients undergoing hip replacement surgery, during and following hospitalization
- in patients undergoing knee replacement surgery
- in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness
Treatment of Acute Deep Vein Thrombosis
Enoxaparin Sodium Injection is indicated for:
- the inpatient treatmentof acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium
- the outpatient treatmentof acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium
Prophylaxis of Ischemic Complications of Unstable Angina and Non-Q-Wave Myocardial Infarction
Enoxaparin Sodium Injection is indicated for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.
Treatment of Acute ST-Segment Elevation Myocardial Infarction
Enoxaparin Sodium Injection, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute ST-segment elevation myocardial infarction (STEMI) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (PCI).
Source: DailyMed label, set id 9e2875df-0f0c-46ec-990f-69108f383f58, version 8, effective October 12, 2026. NDC 68001-457, one of 91 listings for this product.
Enoxaparin Sodium Injection,usp, injection, solution
Indications and Usage, quoted from the label by Sandoz Inc. (ANDA205660). Cross-references to other label sections are left out.
Enoxaparin sodium injection is a low molecular weight heparin (LMWH) indicated for:
- Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness
- Inpatient treatment of acute DVT with or without pulmonary embolism
- Outpatient treatment of acute DVT without pulmonary embolism
- Prophylaxis of ischemic complications of unstable angina and non−Q-wave myocardial infarction (MI)
- Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with subsequent percutaneous coronary intervention (PCI)
Prophylaxis of Deep Vein Thrombosis
Enoxaparin sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):
- in patients undergoing abdominal surgery who are at risk for thromboembolic complications
- in patients undergoing hip replacement surgery, during and following hospitalization
- in patients undergoing knee replacement surgery
- in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness
Treatment of Acute Deep Vein Thrombosis
Enoxaparin sodium injection is indicated for:
- the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium
- the outpatient treatment of acute deep vein thrombosis without pulmonary embolism, when administered in conjunction with warfarin sodium
Prophylaxis of Ischemic Complications of Unstable Angina and Non–Q˗Wave Myocardial Infarction
Enoxaparin sodium injection is indicated for the prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction, when concurrently administered with aspirin.
Treatment of Acute ST-Segment Elevation Myocardial Infarction
Enoxaparin sodium injection, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute ST-segment elevation myocardial infarction (STEMI) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (PCI).
Source: DailyMed label, set id 1e0ac5e2-329c-d0a8-e063-6394a90afba8, version 3, effective October 15, 2026. NDC 0781-3460, one of 35 listings for this product.
Questions
What is enoxaparin used for?
The FDA label for enoxaparin sodium (injection) lists 4 uses: Prophylaxis of Deep Vein Thrombosis; Treatment of Acute Deep Vein Thrombosis; Prophylaxis of Ischemic Complications of Unstable Angina and Non-Q-Wave Myocardial Infarction; Treatment of Acute ST-Segment Elevation Myocardial Infarction.
What drug class is enoxaparin?
FDA lists enoxaparin in the Low Molecular Weight Heparin established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.